IA2030 Scorecard
—Global
- 1.2 Health workforce1.6 Vaccine safety2.1 Political and financial commitment2.2 Demand for immunization3.2 High & equitable coverage4.1 Life-course vaccination5.1 Outbreak detection and response6.1 Healthy global markets for vaccines6.2 Financial resources for imm. programmes6.3 Imm. expenditure from domestic resources7.1 Capacity for innovation
Type to select a Country
Impact Goal 2: Promote Equity
2.2
Provide access to all vaccines
Introduction of new or underutilized vaccines in low- and middle-income countries—Global
180
160
140
120
100
80
60
40
20
0
26
2020
166
2021
45
2022
2030 Target
Average of 50 annual introductions
Target: At least
500
cumulative vaccine introductions in low- and middle-income countries by 2030
On track toward 2030 target
Summary Table
| Vaccine introductions | 2020 | 2021 | 2022 |
|---|---|---|---|
| Total | 26 | 166 | 45 |
| Covid | 4 | 127 | 0 |
| DTP Booster | 0 | 2 | 1 |
| HepB BD | 1 | 0 | 2 |
| HiB | 0 | 0 | 1 |
| HPV | 4 | 4 | 9 |
| IPV2 | 3 | 19 | 17 |
| PCV | 2 | 5 | 3 |
| Rotavirus | 4 | 4 | 1 |
| Rubella | 0 | 0 | 1 |
| Cholera | No Data | No Data | No Data |
| Hep A | 1 | 0 | 0 |
| Influenza | 4 | 1 | 1 |
| JE | 0 | 0 | 0 |
| MenA | 0 | 1 | 2 |
| Multivariant Men | 0 | 0 | 0 |
| Mumps | 1 | 0 | 0 |
| Rabies | No Data | No Data | No Data |
| Typhoid | No Data | No Data | No Data |
| Varicella | 0 | 0 | 0 |
| Yellow Fever | 0 | 0 | 1 |
| MCV2 | 2 | 3 | 6 |
Definition: Number of introductions of new or under-utilized vaccines in low- and middle-income countries based on most recent World Bank income status classification at the time of reporting. Year of introduction is based on the year the vaccine was first reported, including cases where a vaccine was introduced and was suspended or not administered.
- • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in all countries: HepB birth dose, Hib, HPV, IPV2, MCV2, PCV, Rotavirus, Rubella, DTP booster (currently reporting the fourth dose regardless of what age it was administered), and COVID-19 (interim recommendation).
- o Only national introductions are included for the indicator reporting
- o Except for DTP booster, all other vaccines are included based on WHO recommendations – DTP booster is to be revisited in the future to further align with the WHO recommendations
- • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in countries in certain geographic region(s), in some high-risk populations, or in immunization programmes with certain characteristics: YF, JE, MenA, multivariate meningitis, HepA, influenza, varicella, and mumps
- o Typhoid, cholera, dengue, and rabies are included in the IA2030 Framework for Action as part of the indicator reporting but are not being reported on pending further discussions around indicator revision.
Method of estimation: Step 1) Calculate the indicator value. Count the number of introductions of new or under-utilized vaccines in low- and middle-income countries among WHO Member States.
Limitations: Vaccine may have been introduced earlier than reported but reporting is based on official data from the WHO Member States. Although countries report having introduced select vaccines in national immunization schedules, it does not mean children are vaccinated.
Data source: WHO/UNICEF Joint Reporting Form on Immunization (JRF)
Accessed: undefined
